Aldosterone and diabetic kidney disease

Current Diabetes Reports

Volumn 9, Issue 6, 2009, Pages 453-459

  Cha, Dae Ryong ^a   Kang, Young Sun ^b  

^a Korea University   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FARNESOID X RECEPTOR; MINERALOCORTICOID RECEPTOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C JUN; SPIRONOLACTONE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADRENALECTOMY; BLOOD PRESSURE REGULATION; BODY FLUID; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL INFILTRATION; CLINICAL TRIAL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HEART FAILURE; HEMODYNAMICS; HORMONE ACTION; HORMONE BINDING; HORMONE BLOOD LEVEL; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; INSULIN RESISTANCE; KIDNEY FUNCTION; LIPID METABOLISM; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 72849130429     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0074-x     Document Type: Review

References (46)

1. H. Trachtman A.C. Weiser E. Valderrama, et al. 2004 Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction J Urol 172 4Pt2 1590 1594 10.1097/01.ju.0000140445.82949.54 1:CAS:528:DC%2BD2cXnsFejsrY%3D 15371767 (Pubitemid 39244992)
2. I. Feria I. Pichardo P. Juarez, et al. 2003 Therapeutic benefit of spironolactone in experimental cyclosporine A nephrotoxicity Kidney Int 63 43 52 10.1046/j.1523-1755.2003.00707.x 1:CAS:528:DC%2BD3sXmtV2isA%3D%3D 12472767 (Pubitemid 35463905)
3. E.R. Blasi R. Rocha A.E. Rudolph, et al. 2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats Kidney Int 63 1791 1800 10.1046/j.1523-1755.2003.00929.x 1:CAS:528:DC%2BD3sXjslygsb4%3D 12675855 (Pubitemid 36513325)
4. A. Nishiyama Y. Abe 2006 Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade J Pharmacol Sci 100 9 16 10.1254/jphs.FMJ05003X3 1:CAS:528:DC%2BD28Xht1SrtL4%3D 16397374 (Pubitemid 43161608)
5. L. Del Vecchio M. Procaccio S. Vigano D. Cusi 2007 Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade Nat Clin Pract Nephrol 3 42 49 10.1038/ncpneph0362 17183261 (Pubitemid 46020702)
6. K.H. Han Y.S. Kang S.Y. Han, et al. 2006 Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats Kidney Int 70 111 120 10.1038/sj.ki.5000438 1:CAS:528:DC%2BD28XmtlGltrg%3D 16723984 (Pubitemid 44000127)
7. A.H. van den Meiracker R. P. S. Baggen, et al. 2006 Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function J Hypertens 24 2285 2292 10.1097/01.hjh.0000249708.44016.5c 17053552 (Pubitemid 44611039)
8. G.P. Rossi G. Bernini G. Desideri, et al. 2006 Renal damage in primary aldosteronism: results of the PAPY study Hypertension 48 232 238 10.1161/01.HYP.0000230444.01215.6a 1:CAS:528:DC%2BD28XmvFalurg%3D 16801482 (Pubitemid 44309817)
9. R.S. Vasan J.C. Evans M.G. Larson, et al. 2004 Serum aldosterone and the incidence of hypertension in nonhypertensive persons N Engl J Med 351 33 41 10.1056/NEJMoa033263 1:CAS:528:DC%2BD2cXltlOjsLY%3D 15229305 (Pubitemid 38857245)
10. L.A. Sechi M. Novello R. Lapenna, et al. 2006 Long-term renal outcomes in patients with primary aldosteronism JAMA 295 2638 2645 10.1001/jama.295.22.2638 1:CAS:528:DC%2BD28XlvFWmtbo%3D 16772627 (Pubitemid 43882339)
11. J.W. Conn 1965 Hypertension, the potassium ion and impaired carbohydrate tolerance N Engl J Med 273 1135 1143 1:STN:280:DyaF28%2FjvVGjtA%3D%3D 5841677
12. J.R. Sowers A. Whaley-Connell M. Epstein 2009 Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 776 783 19487712
13. A. Hirata N. Maeda A. Hiuge, et al. 2009 Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice Cardiovasc Res 84 164 172 10.1093/cvr/cvp191 1:CAS:528:DC%2BD1MXhtFarsbnP 19505930
14. K.J. Schjoedt S. Andersen P. Rossing, et al. 2004 Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate Diabetologia 47 1936 1939 10.1007/s00125-004-1542-0 1:CAS:528:DC%2BD2cXhtVOqs7vJ 15551047 (Pubitemid 40110201)
15. N.K. Hollenberg R. Stevanovic A. Agarwal, et al. 2004 Plasma aldosterone concentration in the patient with diabetes mellitus Kidney Int 65 1435 1439 10.1111/j.1523-1755.2004.00524.x 1:CAS:528:DC%2BD2cXjtF2js7o%3D 15086486 (Pubitemid 38406985)
16. N. Kobayashi K. Hara A. Tojo, et al. 2005 Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway Hypertension 45 538 544 10.1161/01.HYP.0000157408.43807. 5a 1:CAS:528:DC%2BD2MXisVGlt7c%3D 15710785 (Pubitemid 40411256)
17. C. Guo D. Martinez-Vasquez G.P. Mendez, et al. 2006 Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus Endocrinology 147 5363 5373 10.1210/en.2006-0944 1:CAS:528:DC%2BD28XhtFCgsLvL 16901964 (Pubitemid 44790591)
18. M. Nishimura T. Uzu T. Fujii, et al. 1999 Cardiovascular complications in patients with primary aldosteronism Am J Kidney Dis 33 261 266 10.1016/S0272-6386(99)70298-2 1:STN:280:DyaK1M7ks1answ%3D%3D 10023636
19. H.M. Siragy C. Xue 2008 Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol 93 817 824 10.1113/expphysiol.2008.042085 1:CAS:528:DC%2BD1cXhtVCqu7zE 18296490 (Pubitemid 351904248)
20. A. Sato J.W. Funder 1996 High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes Endocrinology 137 4145 4153 10.1210/en.137.10.4145 1:CAS:528:DyaK28XlvVSnt70%3D 8828470 (Pubitemid 26321859)
21. A. Nishiyama L. Yao Y. Fan, et al. 2005 Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability Hypertension 45 710 716 10.1161/01.HYP.0000154681.38944.9a 1:CAS:528:DC%2BD2MXisV2jtLc%3D 15699469 (Pubitemid 40418370)
22. T. Nishikawa S. Suematsu J. Saito, et al. 2005 Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL) J Steroid Biochem Mol Biol 96 309 316 10.1016/j.jsbmb.2005.03.005 1:CAS:528: DC%2BD2MXntVOhtL8%3D 15993578 (Pubitemid 41080512)
23. I. Juknevicius Y. Segal S. Kren, et al. 2004 Effect of aldosterone on renal transforming growth factor-beta Am J Physiol Renal Physiol 286 F1059 F1062 10.1152/ajprenal.00202.2003 1:CAS:528:DC%2BD2cXkvFCqsLs%3D 15130897 (Pubitemid 38656360)
24. Y.S. Kang G.J. Ko M.H. Lee, et al. 2009 Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats Nephrol Dial Transplant 24 73 84 10.1093/ndt/gfn448 1:CAS:528: DC%2BD1MXhtVKlug%3D%3D 18682491
25. S.Y. Han C.H. Kim H.S. Kim, et al. 2006 Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats J Am Soc Nephrol 17 1362 1372 10.1681/ASN.2005111196 1:CAS:528:DC%2BD28XkvVKrsLs%3D 16571782 (Pubitemid 43673416)
26. G. Fujisawa K. Okada S. Muto, et al. 2004 Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats Kidney Int 66 1493 1502 10.1111/j.1523-1755.2004.00913.x 1:CAS:528:DC%2BD2cXpsVShurg%3D 15458443 (Pubitemid 39298382)
27. D.R. Cha I.S. Kim Y.S. Kang, et al. 2005 Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with type 2 diabetes mellitus Diabet Med 22 14 20 10.1111/j.1464-5491.2004.01295.x 1:CAS:528:DC%2BD2MXhslGktrc%3D 15606685 (Pubitemid 40188280)
28. J.S. Han B.S. Choi C. K. Y. Yang 2009 Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells J Korean Med Sci 24 Suppl S195 S203 10.3346/jkms.2009.24.S1.S195 1:CAS:528:DC%2BD1MXjvVWqt74%3D 19194552
29. H. Yokoi A. Sugawara M. Mukoyama, et al. 2001 Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis Am J Kidney Dis 38 S134 S138 10.1053/ajkd.2001.27422 1:CAS:528:DC%2BD3MXnslKgtrg%3D 11576939
30. S. Gauer V. Segitz M. Goppelt-Struebe 2007 Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor Nephrol Dial Transplant 22 3154 3159 10.1093/ndt/gfm410 1:CAS:528:DC%2BD2sXht1KmtrnL 17602195 (Pubitemid 350202564)
31. N. de las Heras M. Ruiz-Ortega M. Miana, et al. 2007 Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats J Hypertens 25 629 638 10.1097/HJH. 0b013e3280112ce5 17278980 (Pubitemid 46213802)
32. M.L. Gumz M.P. Popp C.S. Wingo B.D. Cain 2003 Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line Am J Physiol Renal Physiol 285 F664 F673 1:CAS:528:DC%2BD3sXosVKisL8%3D 12770840
33. N.J. Brown S. Nakamura L. Ma, et al. 2000 Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo Kidney Int 58 1219 1227 10.1046/j.1523-1755.2000.00277.x 1:CAS:528:DC%2BD3cXmslehtr4%3D 10972684 (Pubitemid 30678044)
34. W. Huang C. Xu K.W. Kahng, et al. 2008 Aldosterone and TGFbeta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells Am J Physiol Renal Physiol 294 F1287 F1295 10.1152/ajprenal.00017.2008 1:CAS:528:DC%2BD1cXnsVarsLk%3D 18367662
35. J. Yuan R. Jia Y. Bao 2007 Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells J Biochem Mol Biol 40 180 188 1:CAS:528:DC%2BD2sXkt1Krur8%3D 17394767
36. N. Banba T. Nakamura M. Matsumura, et al. 2000 Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy Kidney Int 58 684 690 10.1046/j.1523-1755.2000.00214.x 1:CAS:528:DC%2BD3cXlvFagsrY%3D 10916091 (Pubitemid 30620017)
37. L. Lai A. Pen Y. Hu, et al. 2007 Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor Life Sci 81 570 576 10.1016/j.lfs.2007.06.025 1:CAS:528:DC%2BD2sXovFeiu7s%3D 17655877 (Pubitemid 47212237)
38. K. Miyata M. Rahman T. Shokoji, et al. 2005 Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells J Am Soc Nephrol 16 2906 2912 10.1681/ASN.2005040390 1:CAS:528:DC%2BD2MXhtFegtLnM 16135774 (Pubitemid 44743488)
39. M.J. van den Hoven F. Waanders A.L. Rops, et al. 2009 Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species Nephrol Dial Transplant 24 2637 2645 10.1093/ndt/gfp182 19429930
40. A. Sato K. Hayashi T. Saruta 2005 Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease Am J Hypertens 18 44 49 10.1016/j.amjhyper.2004.06.029 1:CAS:528:DC%2BD2MXit1Wms78%3D 15691616 (Pubitemid 40187348)
41. S. Engeli J. Bohnke K. Gorzelniak, et al. 2005 Weight loss and the renin-angiotensin-aldosterone system Hypertension 45 356 362 10.1161/01.HYP.0000154361.47683.d3 1:CAS:528:DC%2BD2MXhtlOis7k%3D 15630041 (Pubitemid 40315803)
42. S. Bianchi R. Bigazzi V.M. Campese 2006 Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease Kidney Int 70 2116 2123 1:CAS:528:DC%2BD28Xht1Kju7bL 17035949
43. S. Arima K. Kohagura H.L. Xu, et al. 2004 Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole Hypertension 43 352 357 10.1161/01.HYP.0000111138.78714.1a 1:CAS:528:DC%2BD2cXitVajsb4%3D 14691200 (Pubitemid 38174138)
44. Y. Furumatsu Y. Nagasawa K. Tomida, et al. 2008 Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker Hypertens Res 31 59 67 10.1291/hypres.31.59 1:CAS:528:DC%2BD1cXltl2ntbo%3D 18360019 (Pubitemid 351325616)
45. B. Pitt W. Remme F. Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D 12668699 (Pubitemid 36384098)
46. M. Epstein G.H. Williams M. Weinberger, et al. 2006 Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 940 951 10.2215/CJN.00240106 1:CAS:528: DC%2BD28XpvFOqsLk%3D 17699311